Discontinuation report ERWINASE
| Report ID | 129623 |
| Drug Identification Number | 02237815 |
| Brand name | ERWINASE |
| Common or Proper name | Erwinia L-asparaginase |
| Company Name | JAZZ PHARMACEUTICALS FRANCE SAS |
| Market Status | MARKETED |
| Active Ingredient(s) | ASPARAGINASE |
| Strength(s) | 10000UNIT |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS |
| Packaging size | 3 mL vials |
| ATC code | L01XX |
| ATC description | OTHER ANTINEOPLASTIC AGENTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 0001-01-01 |
| Actual discontinuation date | |
| Remaining supply date | 2021-02-28 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | A separate communication will be issued regarding the supply of Erwinase by Jazz. |
| Health Canada comments | |
| Contact Address | 84 QUAI CHARLES DE GAULLE CITY ONE LYON, AUVERGNE-RHONE-ALPES FRANCE 69006 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.